Genzyme to jettison three units as it bunkers down

Under assault by Carl Icahn and facing stiff regulatory oversight following some embarrassing manufacturing blunders, Genzyme is getting back to basics. In a series of strategic moves, the biotech company says it will buy back $2 billion worth of its stock as it considers how to rid itself of three businesses that are not part of its core operation. Report